A genetically modified stem cell therapy for Diffuse Large B-Cell Lymphoma (DLBCL) has been approved by the FDA. Researchers at the Abramson Cancer Center, in collaboration with Novartis, have successfully administered a CAR-T Cell therapy, called Kymriah, for the most common type of non-Hodgkin Lymphoma. DLBCL is a fast growing cancer that affects B lymphocytes, which are responsible for producing antibodies that help fight infections in the body. This groundbreaking treatment involves obtaining autologous (the patient’s own) T cells, which are a more specialized type of stem cell, and genetically engineering the cells to track down and destroy cancerous cells.
StemSave Blog
Lymphoma Treatment Utilizing Stem Cells Receives FDA Approval
Posted by maxi@stemsave.com on May 4, 2018 1:08:00 PM
0 Comments Click here to read/write comments
Topics: lymphoma, cancer treatment, stem cell therapy